Skip to content

Ketamine for anxiety: all studies

Page 4 of 19: studies 31 to 40 of 187, newest first. Back to the ketamine for anxiety overview

Research

Repeated 7-day exposure to ketamine induces anxiety-like behaviors and neuronal apoptosis in mice via DRD1-medicated inhibition of Akt/Gsk-3β phosphorylation.

Cell Biology and Toxicology January 30, 2026 Jia-Yi Wei, Peng Lv, Jiayu Zhang et al.

Repeated exposure to ketamine leads to mental behavioral disorders and cognitive deficits in mice. As a neurotransmitter receptor, dopamine receptor 1 (DRD1) is involved in mental regulation and memory formation. However, the role of DRD1 in ketamine's behavioral disorder and neurotoxicity remains unclear. We found that seven-day ketamine exposure induced anxiety-like, depressive-like behavior...

DOI: 10.1007/s10565-026-10149-4 (opens in new tab) Full text (opens in new tab) Anxiety-like behavior Apoptosis Drd1 Ketamine abuse

Symptom trajectories and clinical outcomes of intravenous ketamine in treatment-resistant depression: A real-world study using group-based trajectory modeling.

Journal of Affective Disorders January 23, 2026 Reinhard Janssen-Aguilar, Jithin Joseph, Huda Al-Shamali et al.

Intravenous (IV) ketamine is an emerging intervention for treatment-resistant depression (TRD), yet the temporal dynamics of response and the optimal number of infusions remain unclear, particularly in real-world clinical populations with psychiatric comorbidities. We conducted a retrospective chart review of 209 adults with TRD treated with IV ketamine at an interventional psychiatry program....

Ketamine assisted psychotherapy in postpartum mood and anxiety disorders: a limited case series

Frontiers in Psychiatry January 22, 2026 Alka Christnacht, Therry Rose J Eparwa, Emily Whinkin et al.

The postpartum period is notorious for rapid and profound changes for birthing individuals and their families. Significant shifts to hormonal and physical health, routines and family roles, and the salience of personal and community risk factors all contribute to potential psychiatric and psychological distress for parents, sometimes diagnosed as a postpartum mood or anxiety disorder (PMAD)....

AMELIORATIVE EFFECTS OF SELECTIVE PDE-10 INHIBITORS AGAINST KETAMINE-MEDIATED SCHIZOPHRENIC OUTCOMES IN MICE

Asian Journal of Pharmaceutical and Clinical Research January 7, 2026 Ruchika Srivastava, Prabhat Singh, Ajeet

Objectives: Schizophrenia (SCZ) is characterized by significant impairments in perception and cognitive flexibility. Making accurate plans for therapy demands a deeper comprehension of the brain mechanisms behind these disorders. The purpose of our investigation is to analyze the protective effects of papaverine, a phosphodiesterase-10 inhibitor, on ketamine-induced SCZ -like behavioral and...

Investigation of Esketamine Administration During Surgical Procedures for the Alleviation of Postoperative Anxiety and Depression in Adolescent Patients: A Randomized Controlled Trial.

Drug Design, Development and Therapy 2026 Yanhong Li, Kuangyu Zhao, Peipei Cao et al.

Surgical stress can lead to postoperative anxiety and depression, especially in adolescents. These complications reduce quality of life and increase medical burdens, but perioperative psychological interventions for adolescents are limited, and related mechanisms remain unclear. Esketamine (S-ketamine), an N-methyl-D-aspartate receptor (NMDAR) antagonist, has analgesic, sedative,...

Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review.

General Hospital Psychiatry 2026 Gabrielle F. M. Lovell, Shreya Vasudeva, Diana Orsini et al.

Ketamine is a dissociative anesthetic with potential for treating mood, anxiety, and related disorders; however, concerns have emerged regarding hepatotoxicity in the context of chronic treatment. Systematic searches of PubMed, Scopus, and Ovid databases were conducted from inception to August 2025. Eligible studies included randomized controlled trials (RCTs), observational studies, and case...

Effects of esketamine on postoperative pain, anxiety, depression, sleep, and inflammation in pregnancies undergoing cesarean section: A randomized controlled trial.

PLoS One 2026 Yijun Wang, Xiaolu Lin, Xiang Zou et al.

Postoperative pain is the most notable issue after cesarean section (CS). The contributing factors include hyperalgesia, anxiety, depression, sleep disorders, and inflammation. In this study, we explored the effects of esketamine on pain, hyperalgesia, depression, anxiety, sleep disorders, and inflammation after CS. This randomized, blinded, controlled trial enrolled single-term pregnant women...

Cheung’s Regimen Series: Successful Conversion From One Dose of Esketamine to a Low-Cost Oral Ketamine-Class Glutamatergic Regimen in Treatment-Resistant Depression and OCD

Preprints.org December 2, 2025 Ngo Cheung 1 citation preprint

Intranasal esketamine has proven its worth for patients whose depression will not yield to standard medicines, yet the realities of cost and clinic-based monitoring bar many people from long-term use. The situation is especially frustrating for those who respond spectacularly to a first dose only to watch the benefits fade when they can no longer afford repeat treatments.That was the...

DOI: 10.20944/preprints202512.0185.v1 (opens in new tab) Anxiety Dextromethorphan Regimen Depression economics +7

Ketamine attenuates anxiety-like behavior and oxidative imbalance in the maternal immune activation model: emphasis on the cerebellum.

Psychopharmacology November 28, 2025 Elifrances Galdino de Oliveira, Mayara Victória De Souza Barbosa, Diógenes Afonso De Lima et al.

Relevant to the study of neurodevelopmental disorders, maternal immune activation (MIA) models reproduce the high incidence of anxiety disorders and molecular alterations in the cerebellum reported in patients with schizophrenia and autism. In parallel, ketamine, a fast-acting antidepressant, has shown beneficial effects in psychiatric disorders with immune-related components. To investigate...

Effect of esketamine on postoperative depression and anxiety in patients undergoing cardiac valve surgery: a randomised, placebo-controlled, double-blinded clinical trial.

Pharmacological Research November 22, 2025 Zhuo-Ning Zhang, Xin-Yu Hao, Chen Cai et al. 5 citations

This randomized, double-blind, parallel-group trial evaluated the efficacy of a single intravenous dose of esketamine (0.3mg/kg) administered at anesthesia induction in reducing postoperative depression and anxiety among patients undergoing cardiac valve surgery. A total of 142 patients from three centers were randomly assigned to receive esketamine or saline. The primary outcomes were the...

DOI: 10.1016/j.phrs.2025.108047 (opens in new tab) Full text (opens in new tab) Cardiac valve surgery Esketamine esketamine Postoperative depression Postoperative anxiety +5